Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000116718 | SCV000150689 | likely benign | not specified | 2013-08-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000116718 | SCV000167715 | benign | not specified | 2013-03-15 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Eurofins Ntd Llc |
RCV000116718 | SCV000345969 | benign | not specified | 2016-09-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000463488 | SCV000563072 | benign | Autosomal dominant nocturnal frontal lobe epilepsy | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002313867 | SCV000847944 | likely benign | Inborn genetic diseases | 2016-09-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV003436930 | SCV004150891 | likely benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | CHRNA4: BP4, BP7 |
Breakthrough Genomics, |
RCV003436930 | SCV005210124 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Athena Diagnostics | RCV000116718 | SCV005622664 | benign | not specified | 2024-01-31 | criteria provided, single submitter | clinical testing |